Izervay Becomes Second FDA-Approved Drug for Geographic Atrophy
XTalks
AUGUST 18, 2023
Izervay is the only approved treatment for geographic atrophy that has demonstrated a significant decrease in the rate of geographic atrophy progression at the 12-month primary endpoint, based on results from two rigorous Phase III clinical trials. Izervay contains avacincaptad pegol sodium, an effective complement C5 inhibitor.
Let's personalize your content